1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 234 results for "Multiple Myeloma (MM)".

$Thumbnail for Generalizability Gaps in BCMA- and GPRC5D-Directed Immunotherapy Trials for Relapsed/Refractory Multiple Myeloma: A Trial-Level Eligibility Analysis$

MM - 813

Generalizability Gaps in BCMA- and GPRC5D-Directed Immunotherapy Trials for Relapsed/Refractory Multiple Myeloma: A Trial-Level Eligibility Analysis

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz

Thumbnail for Temporal Trends and Demographic Disparities in Mortality From Multiple Myeloma and Leukemia With Coexisting Coagulation and Hemorrhagic Disorders in the United States, 1999-2024: A CDC WONDER Multiple-Cause Mortality Analysis

MM - 815

Temporal Trends and Demographic Disparities in Mortality From Multiple Myeloma and Leukemia With Coexisting Coagulation and Hemorrhagic Disorders in the United States, 1999-2024: A CDC WONDER Multiple-Cause Mortality Analysis

Madho Mal

Poster Presenter: Madho Mal

SOHO 2026 Annual Meeting

Topics

Generalizability Gaps in BCMA- and GPRC5D-Directed Immunotherapy Trials for Relapsed/Refractory Multiple Myeloma: A Trial-Level Eligibility Analysis

Temporal Trends and Demographic Disparities in Mortality From Multiple Myeloma and Leukemia With Coexisting Coagulation and Hemorrhagic Disorders in the United States, 1999-2024: A CDC WONDER Multiple-Cause Mortality Analysis

Racial Differences in Risk and Latency of Secondary Hematologic Malignancies Following Multiple Myeloma

National Trends in Pneumonia-Related Admissions Among Patients With Multiple Myeloma

GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH SIGNIFICANTLY REDUCED ALL-CAUSE MORTALITY, HOSPITALIZATION, AND SEPSIS IN PATIENTS WITH MULTIPLE MYELOMA AND TYPE 2 DIABETES: A PROPENSITY-MATCHED ANALYSIS OF THE TRINETX GLOBAL COLLABORATIVE NETWORK.

Transformation of Multiple Myeloma Survival in the Novel Therapy Era: From a Once Rapidly Fatal Disease to a Chronic Malignancy

THE IMPACT OF FIRST-LINE DARATUMUMAB ON LIGHT-CHAIN AMYLOIDOSIS SURVIVAL: A REAL-WORLD ANALYSIS OF 70 PATIENTS

Treatment-Related Mortality and Predictors in Real-World Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Multiple Myeloma and Plasma Cell Disorders: Protective, Harmful, or Both? A Scoping Review